Importance Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and
diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis. …

We performed an observational study to investigate intensive care unit incidence, risk factors,
and outcomes of coronavirus disease–associated pulmonary aspergillosis (CAPA). We …

Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic
subtypes have recently been described. Objectives: To use multiple datasets available …

Background Bronchiectasis is a heterogeneous, neglected disease with few multicentre studies
exploring the causes, severity, microbiology, and treatment of the disease across Europe…

Background Bronchiectasis guidelines recommend long-term macrolide treatment for patients
with three or more exacerbations per year without Pseudomonas aeruginosa infection. …

Introduction Rheumatoid arthritis–associated autoantibodies (RA-AAB) can be present in
serum years before clinical onset of rheumatoid arthritis (RA). It has been hypothesized that …

Objective: To investigate whether epileptic seizure activity can be distinguished from non-epileptic
background activity in the neonatal electroenceplalogram (EEG), using …

Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in
people with cystic fibrosis (CF) with ≥ 1 F508del-CFTR allele in Phase 3 clinical trials. ELX/TEZ/…

Rationale Targeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores
chloride channel function and improves epithelial fluid transport in the airways. Consequently, …

Bronchiectasis is a major health problem that is increasing in prevalence and burden globally
[1, 2]. The impact of bronchiectasis on patients and the healthcare system is exacerbated …